

Remarks / Arguments


Claims 2, 3, 4, and 8 are pending in this application. Claim 1 and 5-7 have been canceled. Claims 2 and 3 have been amended. New claim 8 has been added. No new matter has been added.

Claims 5-7 were rejected under §112, first paragraph, on enablement grounds. These claims have now been canceled.

All claims were rejected on grounds of obviousness-type double patenting in view of the claims of earlier patents based on the original filing of this application. The examiner states that the rejection will be overcome if the applicants elect one of the groups R<sup>40</sup> disclosed in original claim 1. Applicants interpret the examiner's statement as a restriction/election of species requirement, although the examiner has not so elaborated his intentions in this regard, and have elected to proceed with a claim to compounds in which the group R<sup>40</sup> is as now shown in new claim 8. They reserve the right to pursue claims to the non-elected subject matter in one or more additional divisional applications.

In view of the above amendments, the claims of this application are deemed to be in condition for allowance, and allowance is accordingly requested.

Respectfully submitted,



William F. Gray  
Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516-4175

Reg. No.: 31018  
Phone: (203) 812-2712  
Date: 10 Nov. 2004